SCHEMBL19206908

SCHEMBL19206908

COC(=O)c1ccccc1Sc1c(Cl)cc(C(F)(F)F)cc1/C=N/[S+]([O-])C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HTT P42858 3/20 0.39
MAPT P10636 6/20 0.38
MRGPRX4 Q96LA9 2/20 0.36
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
POLB P06746 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 2/20 0.34
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18795310 0.90 LMNA (0.49) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795309 0.90 LMNA (0.49) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795817 0.89 POLB (0.39) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795815 0.89 POLB (0.39) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795155 0.88 MAPT (0.40) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795157 0.88 MAPT (0.40) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795192 0.87 MAPT (0.36) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795190 0.87 MAPT (0.36) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795823 0.86 LMNA (0.41) LMNASMN1; SMN2NPSR1HTTMAPT
SCHEMBL18795826 0.86 LMNA (0.41) LMNASMN1; SMN2NPSR1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012466-B2 Peptide macrocycles against Acinetobacter baumannii HOFFMANN-LA ROCHE INC. (US) 2024-06-18 US disclosed
CN-110366556-B Antibacterial peptide macrocyclic compounds and uses thereof 豪夫迈·罗氏有限公司 2024-01-05 CN disclosed
US-20220411468-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII HOFFMANN-LA ROCHE INC. (US) 2022-12-29 US disclosed
EP-3609904-B1 ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF HOFFMANN LA ROCHE (CH) 2022-11-30 EP disclosed
US-11066443-B2 Anti-bacterial peptide macrocycles and use thereof HOFFMANN-LA ROCHE INC. (US) 2021-07-20 US disclosed
EP-3368544-B1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII HOFFMANN LA ROCHE (CH) 2020-06-17 EP disclosed
US-20200040031-A1 ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF HOFFMANN LA ROCHE (US) 2020-02-06 US disclosed
US-20180362578-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII HOFFMANN-LA ROCHE INC. (US) 2018-12-20 US disclosed
EP-3388444-A1 ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF F. Hoffmann-La Roche AG (CH) 2018-10-17 EP disclosed
US-10030047-B2 Peptide macrocycles against acinetobacter baumannii HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-20170233437-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII HOFFMANN-LA ROCHE INC. (US) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066443-B2 Anti-bacterial peptide macrocycles and use thereof CFTR, VIP, NGLY1 LMNA 3511/4885SMN1; SMN2 3708/4885NPSR1 377/4885
US-20220411468-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII VIP, ARG1, CX3CR1 LMNA 3944/4885SMN1; SMN2 4573/4885NPSR1 595/4885
US-12012466-B2 Peptide macrocycles against Acinetobacter baumannii VIP, ARG1, CX3CR1 LMNA 3944/4885SMN1; SMN2 4573/4885NPSR1 595/4885
US-20200040031-A1 ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF CFTR, VIP, NGLY1 LMNA 3511/4885SMN1; SMN2 3708/4885NPSR1 377/4885
US-20180362578-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII VIP, ARG1, CX3CR1 LMNA 3944/4885SMN1; SMN2 4573/4885NPSR1 595/4885
US-20170233437-A1 PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII VIP, ARG1, CX3CR1 LMNA 3944/4885SMN1; SMN2 4573/4885NPSR1 595/4885
US-10030047-B2 Peptide macrocycles against acinetobacter baumannii VIP, ARG1, CX3CR1 LMNA 3944/4885SMN1; SMN2 4573/4885NPSR1 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.